AC Immune Ltd (ACIU) is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Analyst Upgrade/Downgrade Update Brokerage firm: Leerink Partners Change: Coverage Initiated Previous Rating: N/A Current Rating: Outperform Previous Price Target: N/A Current Price Target: N/A
Analyst Upgrade/Downgrade Update Brokerage firm: Credit Suisse Change: Coverage Initiated Previous Rating: N/A Current Rating: Outperform Previous Price Target: N/A Current Price Target: $18
Analyst Upgrade/Downgrade Update Brokerage firm: Jeffries Change: Coverage Initiated Previous Rating: N/A Current Rating: Buy Previous Price Target: N/A Current Price Target: $25
